NEW YORK (Genomeweb News) – AB Sciex today said that it will collaborate with the University of Geneva's Mass Spectrometry Centre on creating new workflows and analytical strategies for improving drug discovery and development.
The firm, which recently was acquired by Danaher, said that the alliance is intended to develop specific applications for use with a "groundbreaking platform that will be the life science industry's first mass spectrometry system to combine both qualitative and quantitative analysis at high resolution and high sensitivity with accurate mass." AB Sciex said that it plans to launch this new platform later this year.
The firm said that researchers at the University of Geneva's Mass Spectrometry Centre are applying the technology now for metabolite identification and are assisting AB Sciex in developing advanced workflows and software applications aimed at accelerating adoption of the new platform within the pharmaceutical industry.
"The new AB Sciex accurate-mass technology is among the most important developments in mass spectrometry technologies in years," Gerard Hopfgartner, professor and scientist at the University of Geneva's Mass Spectrometry Centre, said in a statement. "The ability to integrate qualitative and quantitative analysis within a single platform enables new and better ways to think about conducting experiments."